608 related articles for article (PubMed ID: 25411317)
1. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
2. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
Zhang S; Zhang H; Ghia EM; Huang J; Wu L; Zhang J; Lam S; Lei Y; He J; Cui B; Widhopf GF; Yu J; Schwab R; Messer K; Jiang W; Parker BA; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1370-1377. PubMed ID: 30622177
[TBL] [Abstract][Full Text] [Related]
4. Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells.
Jung EH; Lee HN; Han GY; Kim MJ; Kim CW
Cell Biochem Funct; 2016 Apr; 34(3):149-57. PubMed ID: 26923195
[TBL] [Abstract][Full Text] [Related]
5. Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.
Wu D; Yu X; Wang J; Hui X; Zhang Y; Cai Y; Ren M; Guo M; Zhao F; Dou J
J Immunol Res; 2019; 2019():9394615. PubMed ID: 31008116
[TBL] [Abstract][Full Text] [Related]
6. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C
Oncotarget; 2015 Nov; 6(37):40310-26. PubMed ID: 26515598
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
[TBL] [Abstract][Full Text] [Related]
8. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.
Balakrishnan A; Goodpaster T; Randolph-Habecker J; Hoffstrom BG; Jalikis FG; Koch LK; Berger C; Kosasih PL; Rajan A; Sommermeyer D; Porter PL; Riddell SR
Clin Cancer Res; 2017 Jun; 23(12):3061-3071. PubMed ID: 27852699
[No Abstract] [Full Text] [Related]
9. A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo.
Yin Z; Mao Y; Zhang N; Su Y; Zhu J; Tong H; Zhang H
Biomed Pharmacother; 2019 Nov; 119():109420. PubMed ID: 31536932
[TBL] [Abstract][Full Text] [Related]
10. miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.
Tan H; He Q; Gong G; Wang Y; Li J; Wang J; Zhu D; Wu X
Int J Oncol; 2016 Jan; 48(1):181-90. PubMed ID: 26575700
[TBL] [Abstract][Full Text] [Related]
11. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.
Zhang S; Chen L; Cui B; Chuang HY; Yu J; Wang-Rodriguez J; Tang L; Chen G; Basak GW; Kipps TJ
PLoS One; 2012; 7(3):e31127. PubMed ID: 22403610
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin induces stemness in ovarian cancer.
Wiechert A; Saygin C; Thiagarajan PS; Rao VS; Hale JS; Gupta N; Hitomi M; Nagaraj AB; DiFeo A; Lathia JD; Reizes O
Oncotarget; 2016 May; 7(21):30511-22. PubMed ID: 27105520
[TBL] [Abstract][Full Text] [Related]
13. Targeting ROR1 identifies new treatment strategies in hematological cancers.
Karvonen H; Niininen W; Murumägi A; Ungureanu D
Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
[TBL] [Abstract][Full Text] [Related]
14. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
Vaisitti T; Arruga F; Vitale N; Lee TT; Ko M; Chadburn A; Braggio E; Di Napoli A; Iannello A; Allan JN; Miller LL; Lannutti BJ; Furman RR; Jessen KA; Deaglio S
Blood; 2021 Jun; 137(24):3365-3377. PubMed ID: 33512452
[TBL] [Abstract][Full Text] [Related]
15. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
Dave H; Anver MR; Butcher DO; Brown P; Khan J; Wayne AS; Baskar S; Rader C
PLoS One; 2012; 7(12):e52655. PubMed ID: 23285131
[TBL] [Abstract][Full Text] [Related]
16. Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components.
Leung CS
J Immunol Res; 2018; 2018():2480931. PubMed ID: 29850623
[TBL] [Abstract][Full Text] [Related]
17. Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway.
Won HY; Lee JY; Shin DH; Park JH; Nam JS; Kim HC; Kong G
FASEB J; 2012 Dec; 26(12):5002-13. PubMed ID: 22954590
[TBL] [Abstract][Full Text] [Related]
18. SOX2 expression associates with stem cell state in human ovarian carcinoma.
Bareiss PM; Paczulla A; Wang H; Schairer R; Wiehr S; Kohlhofer U; Rothfuss OC; Fischer A; Perner S; Staebler A; Wallwiener D; Fend F; Fehm T; Pichler B; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
Cancer Res; 2013 Sep; 73(17):5544-55. PubMed ID: 23867475
[TBL] [Abstract][Full Text] [Related]
19. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
[TBL] [Abstract][Full Text] [Related]
20. All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells.
Young MJ; Wu YH; Chiu WT; Weng TY; Huang YF; Chou CY
Carcinogenesis; 2015 Apr; 36(4):498-507. PubMed ID: 25742746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
